HOTAIR and head and neck squamous cell carcinoma: In another study based on human HNSCC samples, cell lines, and xenograft tumors (orthotopic model of UM1 cells in BALB/c nude mice), the authors suggested that STAT3/HOTAIR/EZH2 axis might be a potential therapeutic target for combination therapy of cisplatin and cetuximab in HNSCC patients with PI3K activation [131].